Silver Book Fact

Effectiveness of an oral pharmacologic agent in preventing venous thrombosis

An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.

Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The projected economic value of eliminating deaths from heart disease is approximately $48 trillion.  
  • Performing renal angioplasty to unclog arteries costs $6,000 less than performing a surgical bypass operation. When post-procedure costs are factored in, it costs $14,000 less. The performance of renal angioplasty…  
  • Between 1998 and 2008, the rate of death attributable to cardiovascular disease declined 30.6%.  
  • The volume of mitral valve surgical procedures increased approximately 8.3% from 2010 to 2013.
     
  • Between 1988 & 1994 and 1999 & 2004, use of pharmacological lipid-lowering treatment increased from 11.7% to 40.8%. Low-density lipoprotein cholesterol control increased from 4.0% to 25.1% among those with high…